Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: s. J Biol Chem. 2004. 279(17). 17508-17514. Find at Google Scholar.
Sheaffer, A.K., Mulherin, H.M., Chen, C., Dunaj, C.V., Lee, M.S., Franco, D.L., Campbell, J., Sit, S. Characterization of HCVreplicons resistant to inhibitors of NS3 protease activity. Proceedings of the 7th International Symposiu. 2004. . . Find at Google Scholar.
Seiwert SD, Hon J, Lim SR, Wang T, Tan H, Blatt LM. . Sequence variation of NS3/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those . J Hepatol . 2007. 46. S244-S245. Find at Google Scholar.
Lu L, Pilot-Matias TJ, Stewart KD, et al.. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. . Antimicrob Agents Chemother . 2004. 48. 2260–2266. Find at Google Scholar.
Lagacé Lisette, Peter W. White, Christiane Bousquet, Nathalie Dansereau, Florence Dô, Montse Llinas-. In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335.. Antimicrob Agents Chemother. 2012. 56(1). 569–572. Find at Google Scholar.
He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A. . Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepat. Antimicrob Agents Chemother. . 2008. 52(3). 1101-1110. Find at Google Scholar.
Koev G, Dekhtyar T, Han L, Yan P, Ng TI, Lin CT, Mo H, Molla A. . Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon i. Antiviral Res. . 2007. 73(1). 78-83. Find at Google Scholar.
Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong A. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely. J Virol. . 2013. 87(3). 1544-1553. Find at Google Scholar.
Vermehren J, Susser S, Lange CM, Forestier N, Karey U, Hughes E, Ralston R, Tong X, Zeuzem S, Sarraz. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boc. J Viral Hepat. . 2012. 19(2). 120-127. Find at Google Scholar.
Bae A, Sun SC, Qi X, Chen X, Ku K, Worth A, Wong KA, Harris J, Miller MD, Mo H. . Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibito. Antimicrob Agents Chemother. . 2010. 54(12). 5288-5297. Find at Google Scholar.
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban. Telaprevir for retreatment of HCV infection. . N Engl J Med. . 2011. 364(25). 2417-2428. Find at Google Scholar.